Protara Therapeutics Inc（TARA）财务数据TARAProtara Therapeutics Inc

Evaluating the bottom line, Protara Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -45.80%, provide a clear picture of how effectively TARA converts its operational activities into shareholder value.

In the context of the broader market, TARA competes directly with industry leaders such as SLGL and NERV. With a market capitalization of $234.61M, it holds a significant position in the sector. When comparing efficiency, TARA's gross margin of N/A stands against SLGL's N/A and NERV's N/A. Such benchmarking helps identify whether Protara Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Protara has reported consistent net losses, with a net income of -$21.7 million in Q2 2026 and an EPS of -0.36, indicating challenges in achieving profitability. Despite this, the company maintains a strong cash position with $177.4 million in cash reserves as of March 2026, sufficient to fund operations through 2028.